Acute coronary syndrome - rivaroxaban [ID532]: committee papers
Acute coronary syndrome - rivaroxaban [ID532]: Committee Papers
Table of Contents
01. NICE's response to comments on the Appraisal Consultation Document (ACD)
02. Consultee/ comments on the ACD - Bayer
03. Consultee/ comments on the ACD - DH
04. Consultee/ comments on the ACD - Royal College of Nursing
05. Clinical comments on the ACD - Di Marlo
06. Public comments on the ACD received via the NICE website
Acute coronary syndrome - rivaroxaban [ID532]: committee papers
23 January 2015 (982.19 Kb 46 sec) |
This page was last updated: 19 January 2015